Hormone suppression achieves a response rate of more than 75% and is therefore a valid alternative in the management of metastatic cancer of the prostate. Monotherapy and total androgen blockade have similar survival rates and disease free intervals. However, the results according to prognostic groups are significantly better for those treated with total androgen blockade and has less severe disease, suggesting early treatment.
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
This record was last updated on 07/02/2016 and may not reflect the most current and accurate biomedical/scientific data available from NLM.
The corresponding record at NLM can be accessed at https://www.ncbi.nlm.nih.gov/pubmed/9494195